Is Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Cheap As ADC Pipeline News Builds?
Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) is back in focus after Chinese regulators accepted a new indication application for its TROP2-directed ADC sacituzumab tirumotecan in first-line triple-negative breast cancer.
See our latest analysis for Sichuan Kelun-Biotech Biopharmaceutical.
The regulatory momentum around sacituzumab tirumotecan and SKB565 comes alongside a 26.81% year to date share price return and a very large 3 year total shareholder return of about 7x. This suggests interest in Sichuan Kelun-Biotech Biopharmaceutical is building again despite a softer 1 month share price return.
If you are looking for more ideas in high growth healthcare and biotech, this is a good moment to scan a curated list of 128 healthcare AI stocks
The recent surge in Sichuan Kelun-Biotech Biopharmaceutical, alongside its stronger three year return, may reflect growing conviction in the ADC pipeline rather than just short term enthusiasm. How does that balance look once you test the valuation?
Most Popular Narrative: 9.8% Undervalued
Against a last close of HK$508.0, the most followed narrative pegs Sichuan Kelun-Biotech Biopharmaceutical’s fair value at HK$563.10, which points to a modest valuation gap built on long dated ADC and partnership assumptions.
The broad adoption of antibody drug conjugates in cancer treatment, combined with Kelun-Biotech's OptiDC platform and 9 ADC projects in the clinic, positions the company to add indications and products that can widen the revenue base over time.
Partnerships with global pharmaceutical groups such as Merck, Ellipses and Crescent Bio, including 17 ongoing global Phase III trials, create a route for overseas launches, milestones and royalties that can supplement domestic product sales and earnings.
Curious what sits behind that HK$563.10 figure? The narrative leans on rapid revenue expansion, a sharp swing from losses to profits, and a premium future earnings multiple. Want to see how those moving parts fit together and what assumptions really drive that valuation call?
Result: Fair Value of HK$563.10 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Sichuan Kelun-Biotech Biopharmaceutical still faces clear risks if late stage ADC trials disappoint or if partnered milestones and royalties fall short of expectations.
Find out about the key risks to this Sichuan Kelun-Biotech Biopharmaceutical narrative.
Another View on Sichuan Kelun-Biotech Biopharmaceutical’s Valuation
The narrative and analyst work suggest Sichuan Kelun-Biotech Biopharmaceutical is undervalued on projected earnings and cash flows. The simple reality today is that the stock trades on a P/B of 21.5x, compared with 3.7x for the Hong Kong Biotechs industry and 6.5x for peers. This points to a clearly richer valuation that could matter if growth or profitability expectations change.
See what the numbers say about this price in more detail by reviewing the See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With sentiment on Sichuan Kelun-Biotech Biopharmaceutical leaning positive, this is a good time to review the full data set and form your own stance. To see what investors are most optimistic about, start with the 2 key rewards
Looking for more investment ideas beyond Sichuan Kelun-Biotech Biopharmaceutical?
If Sichuan Kelun-Biotech Biopharmaceutical has caught your attention, do not stop there. Broaden your watchlist with focused screeners that surface fresh opportunities across sectors.
- Target potential opportunities that the market may be underpricing by reviewing the 251 high quality undervalued stocks tailored to strong fundamentals.
- Strengthen your search around companies with healthier balance sheets by scanning the solid balance sheet and fundamentals stocks screener (422 results) that filters for financial resilience.
- Identify possible future standouts early by checking the screener containing 548 high quality undiscovered gems that highlights quality stocks still flying under most investors' radar.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com